Daniel K. Rasmussen

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.

Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.

Journal: American journal of physiology. Cell physiology

Published: August 17, 2026

Extracellular matrix proteins as risk markers for complications in type 1 diabetes.

Extracellular matrix proteins as risk markers for complications in type 1 diabetes.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: February 12, 2026

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.

Journal: Journal of hepatology

Published: November 14, 2025

Urinary endotrophin as a biomarker for T cell-mediated rejection-associated fibrogenesis in kidney transplant recipients.

Urinary endotrophin as a biomarker for T cell-mediated rejection-associated fibrogenesis in kidney transplant recipients.

Journal: Clinical kidney journal

Published: March 17, 2025

Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy.

Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy.

Journal: Frontiers in endocrinology

Published: September 12, 2024

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.

Journal: Diabetes, obesity & metabolism

Published: April 18, 2024

The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases.

The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases.

Journal: Matrix biology : journal of the International Society for Matrix Biology

Published: April 18, 2024

Extracellular matrix turnover proteins as risk markers in people with type 2 diabetes and microalbuminuria.

Extracellular matrix turnover proteins as risk markers in people with type 2 diabetes and microalbuminuria.

Journal: Journal of diabetes and its complications

Published: February 09, 2024

Urinary Endotrophin and Long-term Outcomes in Kidney Transplant Recipients.

Urinary Endotrophin and Long-term Outcomes in Kidney Transplant Recipients.

Journal: Transplantation direct

Published: December 07, 2023

Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats.

Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats.

Journal: American journal of physiology. Endocrinology and metabolism

Published: October 04, 2023

Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes.

Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes.

Journal: Biomedicines

Published: October 03, 2023

Endotrophin, a Collagen VI Formation-Derived Peptide, in Heart Failure.

Endotrophin, a Collagen VI Formation-Derived Peptide, in Heart Failure.

Journal: NEJM evidence

Published: August 30, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026